J.P.
Piper Jaffray’s healthcare analyst Joshua Schimmer is weighing in on Gilead Sciences’ (NASDAQ:GILD), after the company reported a solid fourth-quarter performance led by the HCV franchise, but conservatively guided below …
In a research report sent to investors today, Needham analyst Alan Carr reiterated a Buy rating on Gilead Sciences (NASDAQ:GILD) with a price target …
Another rough and tumble week ending with the SP 500 down sharply 3 straight days ending the week around 1994, just 4 points …
Wall Street has an exciting week ahead as three big name stocks are scheduled to announce their latest quarterly earnings. Gilead Sciences (NASDAQ: GILD): …
Needham’s healthcare analyst Alan Carr weighed in this morning with a few insights on Gilead Sciences (NASDAQ:GILD), as the company is scheduled to report its …
Earnings season unofficially kicks off today after the closing bell when Alcoa (NYSE:AA) releases results for the fourth quarter. Current estimates paint a …
Deutsche Bank analyst Robyn Karnauskas came out today with an update on Gilead Sciences (NASDAQ:GILD), following the news that Anthem Inc. (NYSE:ANTM) chose GILD’s hepatitis C drug …
